Calidi Biotherapeutics, Inc. Amortization of Debt Discount (Premium)
Calidi Biotherapeutics, Inc. (CLDI) reported Amortization of Debt Discount (Premium) of $45.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-03-27
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $4.00K.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $9.00K, a 95.52% decline year-over-year.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $16.00K, a 3.17% decline year-over-year.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $16.00K, a 92.04% decline year-over-year.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for fiscal 2024 was $45.00K, a 89.58% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for fiscal 2023 was $432.00K, a 251.22% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. amortization of debt discount (premium) for fiscal 2022 was $123.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 6 month as first filed | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $13.00K derived: sum of 2 quarters · filed 2026-03-27 | $29.00K derived: sum of 3 quarters · filed 2026-03-27 | $45.00K 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $25.00K derived: sum of 2 quarters · filed 2025-11-13 | $41.00K 10-Q · filed 2025-11-13 | -$238.00K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $32.00K 10-Q · filed 2025-08-08 | -$247.00K derived: sum of 3 quarters · filed 2025-08-08 | -$46.00K derived: sum of 4 quarters · filed 2025-08-08 | ||
| 2024-03-31 | $16.00K 10-Q · filed 2025-05-14 | -$263.00K derived: sum of 2 quarters · filed 2025-05-14 | -$62.00K derived: sum of 3 quarters · filed 2025-05-14 | -$45.48K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$78.00K derived: sum of 2 quarters · filed 2025-03-31 | -$61.48K derived: sum of 3 quarters · filed 2025-03-31 | $432.00K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $217.52K derived: sum of 2 quarters · filed 2024-11-12 | $711.00K 10-Q · filed 2024-11-12 | $537.52K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $16.52K 10-Q · filed 2023-08-21 | $510.00K 10-Q · filed 2024-08-13 | $32.87K 10-Q · filed 2023-08-21 | $336.52K derived: sum of 3 quarters · filed 2024-05-14 | ||
| 2023-03-31 | $201.00K 10-Q · filed 2024-05-14 | $16.34K 10-Q · filed 2023-05-15 | $320.00K derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $123.00K 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $4.00K 10-Q · filed 2023-11-14 | |||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |